Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-421-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.54 million
Profitability
Miscellaneous
Employees162
OptionableOptionable
Dermira (NASDAQ:DERM) Frequently Asked Questions
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira Inc (NASDAQ:DERM) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.63) by $0.05. The biopharmaceutical company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.80 million. Dermira had a negative net margin of 496.49% and a negative return on equity of 184.43%. View Dermira's Earnings History.
When is Dermira's next earnings date?
What price target have analysts set for DERM?
7 brokers have issued 12 month target prices for Dermira's shares. Their forecasts range from $6.71 to $25.00. On average, they anticipate Dermira's share price to reach $16.2850 in the next twelve months. This suggests a possible upside of 152.9% from the stock's current price. View Analyst Price Targets for Dermira.
What is the consensus analysts' recommendation for Dermira?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.
What are Wall Street analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/14/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post DERM’s solid quarter of execution, we reiterate our OW rating and 12-month price target of $20 for DERM shares. We think there is not enough value being attributed to DERM’s two key assets: 1) Qbrexza (glycopyrronium) for hyperhidrosis (excessive sweating) and 2) lebrikizumab for atopic dermatitis. The launch of Qbrexza and pipeline advancements for lebrikizumab should drive upward earnings revisions to levels not yet reflected in sell-side consensus expectations and DERM’s stock higher." (11/7/2018)
- 3. Mizuho analysts commented, "We previously modeled $302.5M for and our estimate remains relatively unchanged. We reiterate our Neutral rating and $10 PT." (10/2/2018)
Has Dermira been receiving favorable news coverage?
Headlines about DERM stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dermira earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB) and ImmunoGen (IMGN).
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)
- Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)
- Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 50)
- Mr. Luis C. Peña, Chief Devel. Officer (Age 55)
- Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 41)
Who are Dermira's major shareholders?
Dermira's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Midwest Bank Trust Division (1.05%) and Virtu Financial LLC (0.04%). Company insiders that own Dermira stock include Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Matthew K Fust, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.
Which major investors are buying Dermira stock?
DERM stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and Virtu Financial LLC. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira.
How do I buy shares of Dermira?
Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of DERM stock can currently be purchased for approximately $6.44.
How big of a company is Dermira?
Dermira has a market capitalization of $286 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe.
What is Dermira's official website?
How can I contact Dermira?
Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]
MarketBeat Community Rating for Dermira (NASDAQ DERM)
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
